A-ring reduction enhances the antigonadotropic potency of norethisterone - PubMed

A-ring reduction enhances the antigonadotropic potency of norethisterone

J Garza-Flores et al. Acta Endocrinol (Copenh). 1986 Jun.

Abstract

To assess whether structural modifications on the A-ring of norethisterone (NET) could modify its antigonadotropic potency, comparative studies using NET, 5 alpha-dihydro NET (5 alpha-NET) and its 3 beta,5 alpha and 3 alpha,5 alpha tetrahydro derivatives in castrated adult rats were undertaken. The antigonadotropic effect of these compounds was evaluated by measuring the serum and pituitary immunoreactive concentrations of LH and FSH following their chronic sc administration to animals depleted of progesterone receptors. The results demonstrated that 3 beta,5 alpha-NET and 5 alpha-dihydro-NET exhibited a significantly greater gonadotropic inhibiting activity as compared with that of their parent compound. The simultaneous administration of tamoxifen with 3 beta,5 alpha-NET resulted in a significant diminution of its antigonadotropic potency, particularly for LH. These data indicate that the potent antigonadotropic effect of 3 beta,5 alpha-NET metabolite was mediated via oestrogen receptors. The LH inhibitory activity of 5 alpha-dihydro-NET was not suppressed by the non-steroidal antioestrogen administration, thus suggesting that 5 alpha-NET might exert its effect via androgen receptors. The overall data were interpreted as demonstrating that metabolic conversion products of NET exhibit potent antigonadotropic effect. The data are consistent with an A-ring enhancement of the antigonadotropic potency of this synthetic progestin and open an alternate approach to the development of fertility regulating agents.

Similar articles

• Further studies on the antigonadotropic mechanism of action of norethisterone.

  Garza-Flores J, Menjívar M, Cardenas M, Reynoso M, García GA, Pérez Palacios G. Garza-Flores J, et al. J Steroid Biochem Mol Biol. 1991 Jan;38(1):89-93. doi: 10.1016/0960-0760(91)90406-u. J Steroid Biochem Mol Biol. 1991. PMID: 1825472

• 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.

  Lemus AE, Enríquez J, García GA, Grillasca I, Pérez-Palacios G. Lemus AE, et al. J Steroid Biochem Mol Biol. 1997 Jan;60(1-2):121-9. doi: 10.1016/s0960-0760(96)00172-0. J Steroid Biochem Mol Biol. 1997. PMID: 9182866

• The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor.

  Couzinet B, Young J, Brailly S, Chanson P, Thomas JL, Schaison G. Couzinet B, et al. J Clin Endocrinol Metab. 1996 Dec;81(12):4218-23. doi: 10.1210/jcem.81.12.8954018. J Clin Endocrinol Metab. 1996. PMID: 8954018 Clinical Trial.

• Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progestin receptors.

  Vilchis F, Chávez B, Pérez AE, García GA, Angeles A, Pérez-Palacios G. Vilchis F, et al. J Steroid Biochem. 1986 Feb;24(2):525-31. doi: 10.1016/0022-4731(86)90115-9. J Steroid Biochem. 1986. PMID: 3702437

• The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level.

  Larrea F, Vilchis F, Chávez B, Pérez AE, Garza-Flores J, Pérez-Palacios G. Larrea F, et al. J Steroid Biochem. 1987;27(4-6):657-63. doi: 10.1016/0022-4731(87)90134-8. J Steroid Biochem. 1987. PMID: 3320552 Review.

Publication types

MeSH terms

Substances